Exagen Inc. (NASDAQ: XGN) reported Q3 EPS of ($0.47), $0.29 better than the analyst estimate of ($0.76). Revenue for the quarter came in at $14.7 million versus the consensus estimate of $9.13 million.

GUIDANCE:

Exagen Inc. sees FY2022 revenue of $40-43 million, versus the consensus of $38 million.

For earnings history and earnings-related data on Exagen Inc. (XGN) click here.